Genfit S.A.
NASDAQ: GNFT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- M. Pascal Prigent
- Employees
- 180
- Headquarters
- Loos, France
- IPO year
- 2019
- Market cap
- $445.7M
- Website
- https://www.genfit.com
Loading GNFT…
Loading profile data…Frequently asked questions about GNFT
What does Genfit S.A. (GNFT) do?
Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (...
Where does GNFT trade?
Genfit S.A. (GNFT) trades on the NASDAQ Global Select.
What sector is GNFT in?
Genfit S.A. (GNFT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genfit S.A.?
M. Pascal Prigent is the chief executive officer of Genfit S.A. (GNFT).
Where is Genfit S.A. headquartered?
Genfit S.A. is headquartered in France.
Does GNFT pay a dividend?
Genfit S.A. (GNFT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GNFT go public?
Genfit S.A. (GNFT) completed its initial public offering in 2019.
Is GNFT an ADR?
Yes — GNFT is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Genfit S.A. reporting and dividends follow the underlying issuer.